RxDoctor Payments Data

Sierra Eames, NP

Family · Houston, TXNPI 1609561521

Payments from drug & device makers

$2,374in general payments, 2019–2025

Across 67 payments — averaging $35.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$741
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$638
  • Abbott$338
  • Bard Peripheral Vascular, Inc.$152
  • Silk Road Medical, Inc.$112
  • AstraZeneca$95
  • plus $299 from 9 others

What the payments were for

  • Food & beverage$2,374100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,374 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$32,155
Medicare patients
251
Services billed
358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban22$12,862
FarxigaDapagliflozin Propanediol22$12,115
EntrestoSacubitril/Valsartan13$11,607
BrilintaTicagrelor19$8,545
ClopidogrelClopidogrel Bisulfate69$636
Rosuvastatin Calcium13$478
Atorvastatin Calcium32$445
Diltiazem 24hr Er (Cd)Diltiazem Hcl15$388
Pantoprazole Sodium42$337
Nitroglycerin31$299
Metoprolol Succinate33$268
Carvedilol25$208
Amiodarone Hcl18$160
Metoprolol Tartrate22$114
Spironolactone14$85

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$95$20,66041 claims
PfizerEliquis$30$12,86222 claims
NovartisEntresto$13$11,60713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 15,456 family providers in Texas.

Other family in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →